Cognition Therapeutics, Inc. (NASDAQ: CGTX) shares faltered Tuesday, as the company, a clinical-stage company developing drugs that treat neurodegenerative disorders, will be presenting biomarker results from the Phase 2 SHINE (COG0201) study of zervimesine (CT1812) in mild-to-moderate Alzheimer’s disease at the AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Conference taking place April 1-5 in Vienna.
Mary Hamby, Ph.D., Cognition Therapeutics’ VP of research will present findings from the SHINE study during a podium presentation at the conference. Her address will focus on the analysis of key proteins, called biomarkers, that were collected in blood samples during the study. Biomarkers of interest include neurofilament light (NfL) chain, glial fibrillary acidic protein (GFAP), amyloid beta (Aß), and tau species (p-Tau217 and p-Tau218), all of which are associated with the progression of Alzheimer’s disease.
Dr. Hamby explained, “We can gain insight on the impact of zervimesine on disease biology by assessing changes in these biomarkers in participants receiving zervimesine compared to those receiving placebo. Taken together with the positive cognitive and functional findings, these biomarker findings give us a more complete understanding of the drug’s impact on the disease.”
“We are currently investigating our lead candidate, zervimesine,” reads this morning’s news release, “in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease, including the ongoing START study in early Alzheimer’s disease.”
CGTX shares began trading behind two cents, or 5.6%, to 47 cents.
